Iovance Biotherapeutics makes Amtagvi, a personalized cell therapy for advanced melanoma, and sells Proleukin, a related cancer drug. It last closed at $7.53 on Nov 17, down 0.26% on the day. The average 12-month price target from 8 analysts is $14.13 (+87.6% from the last close), with a high of $20.00 and a low of $8.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (6 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in IOVA, 100% of them bullish and 0% bearish. In the past 30 days there were 4 dark pool prints totaling $1.1M, the largest $352K.
Each firm's latest rating on IOVA in the past 90 days
Average 12-month target
$14.13
▲ 87.6% upside
Based on 8 analysts who set a price target on IOVA in the past 90 days. The average target is $14.13, with a high of $20.00 and a low of $8.00, compared with the last close of $7.53.
Highest target$20.00
Average target$14.13
Lowest target$8.00
Latest rating changes
BarclaysTarget raised
Nov 6Buy$18 → $19
CitizensTarget raised
Nov 6Buy$8 → $12
UBSTarget raised
Nov 3Hold$7 → $8
BarclaysTarget raised
Oct 13Buy$15 → $18
BairdMaintained
Oct 8Hold$11
Date
Firm
Action
Rating
Price target
Nov 6
Barclays
Target raised
Buy
$18 → $19
Nov 6
Citizens
Target raised
Buy
$8 → $12
Nov 3
UBS
Target raised
Hold
$7 → $8
Oct 13
Barclays
Target raised
Buy
$15 → $18
Oct 8
Baird
Maintained
Hold
$11
Loading…
Technical Analysis
IOVA · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold
The stock is 33% below its 20 day and 50% below its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot at $7.52, and the nearest resistance the Pivot R1 at $7.78.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.3%/day
Key levels
$15.3752 week high+104.1%
$11.2950 day average+49.9%
$10.0120 day average+32.9%
$8.91Swing high (Sep 8)+18.3%
$8.64100 day average+14.7%
$7.78Pivot R1+3.3%
$7.53Last close
$7.52Pivot−0.1%
$7.27Pivot S1−3.5%
$6.16200 day average−18.2%
$3.96Swing low (Aug 3)−47.4%
$2.0852 week low−72.4%
Indicators
RSI (14)
31.75
Weak, oversold below 30
Neutral
MACD
-1.32
Below its signal line
Bearish
Stochastic
3.9
Near the bottom of its range
Oversold
ADX (14)
40.2
Strong downtrend
Williams %R
-93.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-66.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−14.7%
Change over 10 sessions
Bearish
ATR (14)
$0.85
Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityHigh, 22.6%/day
Key levels
$15.3752 week high+104.1%
$11.2950 day average+49.9%
$10.0120 day average+32.9%
$8.91Swing high (Sep 8)+18.3%
$8.64100 day average+14.7%
$7.78Pivot R1+3.3%
$7.53Last close
$7.52Pivot−0.1%
$7.27Pivot S1−3.5%
$6.16200 day average−18.2%
$3.96Swing low (Aug 3)−47.4%
$2.0852 week low−72.4%
Indicators
RSI (14)
47.79
Middle of its range
Neutral
MACD
1.26
Below its signal line
Bearish
Stochastic
20.9
Middle of its range
Neutral
ADX (14)
51.3
Strong uptrend
Williams %R
-90.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-31.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−12.4%
Change over 10 sessions
Bearish
ATR (14)
$1.70
Typical daily range, 22.6% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for IOVA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IOVA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IOVA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IOVA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IOVA is in one of them and how their past IOVA trades turned out.
Iovance Biotherapeutics develops and sells cell therapies that use a patient's own immune cells to fight solid tumor cancers. Its main product, Amtagvi, is a single, personalized treatment for adults with advanced melanoma who have had prior treatment, and it is given at treatment centers. The company also sells Proleukin, an interleukin-2 product used in the Amtagvi treatment regimen and in other medical uses, through distributors and other clients. Based in San Carlos, California, Iovance serves cancer treatment centers and is developing therapies for other solid tumors.